Stocks of Chinese pharmaceutical companies posted the worst drop in almost a decade after the drug prices in the government procurement tumbled, sparking concerns that in the future companies will have to make sharp price cut to win government order.
Preliminary results for the tender on Thursday shows that prices on drugs that made into a government procurement list were cut substantially. In particular, the price for one hepatitis B drug was cut by as much as 90 per cent and the price of another made by Jiangsu Hengrui Medicine Co. was reduced by 60 per cent.
The result has . . .
To continue reading, please subscribe.
We highly value independence. Yuan Talks is solely funded by subscriptions from readers like you.
What you'll get:
- High-quality & in-depth reporting on the most important topics about China's economy and financial markets
- Daily Brief newsletter to give you a full picture of what's happening in China every weekday
- Interviews with China experts
- Conference calls and events
We are not content with general information that you can get everywhere. We go deeper to get details, data and perspectives you won't read elsewhere!
Already have an account? Sign In